within Pharmacolibrary.Drugs.ATC.L;

model L04AC10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.1666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0070999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0037,
    k12             = 0.36,
    k21             = 0.36
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AC10</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases. It is primarily used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Secukinumab is an approved drug and is in regular clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics of secukinumab in adults with moderate to severe plaque psoriasis after subcutaneous administration.</p><h4>References</h4><ol><li><p>Yao, F, et al., &amp; Hu, W (2024). A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx. <i>Drug design, development and therapy</i> 18 3891–3901. DOI:<a href=\"https://doi.org/10.2147/DDDT.S470619\">10.2147/DDDT.S470619</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39224901/\">https://pubmed.ncbi.nlm.nih.gov/39224901</a></p></li><li><p>Shirley, M, &amp; Scott, LJ (2016). Secukinumab: A Review in Psoriatic Arthritis. <i>Drugs</i> 76(11) 1135–1145. DOI:<a href=\"https://doi.org/10.1007/s40265-016-0602-3\">10.1007/s40265-016-0602-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27299434/\">https://pubmed.ncbi.nlm.nih.gov/27299434</a></p></li><li><p>Blair, HA, &amp; Dhillon, S (2016). Secukinumab: A Review in Ankylosing Spondylitis. <i>Drugs</i> 76(10) 1023–1030. DOI:<a href=\"https://doi.org/10.1007/s40265-016-0598-8\">10.1007/s40265-016-0598-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27255593/\">https://pubmed.ncbi.nlm.nih.gov/27255593</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AC10;
